CS use has been shown to cause long-term adverse effects, which include diabetes, increased susceptibility to infection, obesity, hypertension, hyperlipidemia, osteopenia, cataracts and growth retardation in children. CS have also been implicated in accelerating Hepatitis C (HCV) recurrence post-OLT (2-3). Consequently, several clinical trials which adopted early CS reduction and cessation after OLT were conducted and showed no increase in safety risks (4) (5) (6) . In recent years, a small but increasing proportion of transplant centers, including our group, have demonstrated that adult and pediatric OLT may be successfully performed with CS minimization (7) (8) (9) (10) (11) .
Prior to this study the standard immunosuppressive protocol at Thomas Jefferson University Hospital (TJUH) for OLT recipients included basiliximab induction and CS intraoperatively, followed by calcineurin inhibitor (CNI), mycophenolate mofetil (MMF), and CS maintenance therapy.
RESULTS
Between February 2006 and November 2007, forty adult OLT recipients were enrolled in the study and 20 recipients were randomized to each group. One recipient in the CS-free group required a re-transplantation for hepatic artery thrombosis on post-OLT day 16 . Since he expired within 10 days after re-transplantation, follow up data was short and untenable and therefore, he was excluded from the study analysis.
The mean overall follow-up was 47.3 months as of July 2011. Donor characteristics were comparable between the two groups ( Table 1) . Other than a significantly higher mean recipient age and longer mean hospital stay in group B compared to group A, recipient demographics and peri-operative data were similar between the two groups. There were 3 outliers in group B with mean hospital stay of 67.7 (range: 43-89) days. One had a protracted surgical ICU stay due to prolonged ventilator dependence, atrial fibrillation, and poor mental status. Another patient had ventilator-dependent adult respiratory distress syndrome, hepatopulmonary syndrome, acute renal failure, sepsis, and massive colonic bleeding. The third patient had a MELD score of 35 at OLT with hepato-renal syndrome (Table 1) .
Primary end points
There was no significant difference in patient and death-censored graft survival rates between the 2 groups. The 1-, 3-, and 5-year patient survival rates in group A and group B, respectively were: 100% vs. 94%, 85% vs. 63%, and 85% vs. 63% (Figure1). The 1-, 3-, and 5-year graft survival rates in group A and B, respectively were: 100% vs. 100%, 85% vs. 79%, and 85% vs. 79% (Figure 2 ). There were 10 deaths, 3 in group A and 7 in group B. The causes of death in group A were: cerebrovascular accident (n=1), and liver failure secondary to severe progressive HCV recurrence (n=2). In group B, the causes of death were: cerebrovascular accident (n=1), necrotizing pancreatitis post-endoscopic retrograde cholangiopancreatography (n=1), self-inflicted gun shot wound to the head (n=1), and liver failure secondary to severe progressive HCV recurrence (n=4). The mean time to death from OLT was 21.5 months in group A and 24.7 months in group B (p= ns). CS-responsive biopsyproven acute rejection occurred once in 1 patient (5%) in each group.
Secondary end points.
The mean peak aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and international normalized ratio (INR) levels and the mean days to peak post-OLT were similar between the 2 groups. The time to transaminase peak occurred on POD 2 and POD 1 in groups A and B, respectively, while the mean time to INR peak was <1day for both groups. Furthermore, there was no incidence of primary non-function in this cohort ( Table 2 ).
The mean weight decreased in group A and group B from baseline to one month post-OLT. However, from 1-month to 1-year post-OLT, mean weight increased steadily in group A but decreased in group B, although the difference was not significant. Mean cholesterol levels were similar in both groups from baseline to 12 months post-OLT. The mean arterial pressure (MAP) in group A increased from baseline to 3 months before they started to decrease by 6 months post-OLT. Likewise, MAP in group B increased from baseline to 1 month before they trended downwards by the 3 rd month post-OLT. Mean FBS levels at baseline, 1, 3, and 12 months post-OLT were similar, except at 6 months post-OLT when FBS levels were significantly higher (p=0.02) in group A compared to group B. Eight recipients in each group developed NODM with mean FBS levels (mg/dl) of 148 and 152 in group A and B, respectively (Table 2 ). There were more HCV recipients in group B (74%) than in group A (55%). We also observed an earlier peak (1 vs. 3 months post-OLT) and higher HCV PCR levels (16 million vs. 11.9 million, p=ns) in group A than in group B. However, the incidence and severity of HCV recurrence were similar in both groups based on liver biopsy results. Anti-viral treatment outcomes are listed in Table 3 .
Mean tacrolimus trough levels (ng/ml) were similar at 1, 3, 6, and 12 month post-OLT in group A (11.3, 9, 7.8, 7.5) and B (8.1, 7.8, 9.4, 6), respectively. The mean duration on CS was 174 days in Group A. EC-MPS was given for a mean duration of 2.9 months post-OLT in both groups. EC-MPS dose reduction was carried out for gastro-intestinal symptoms (diarrhea, vomiting) in 4 patients in each group; and for neutropenia in 3 and 6 recipients in group A and B, respectively. EC-MPS was discontinued for GI symptoms in 1 recipient in each group; and for neutropenia in 2 and 1 recipient in group A and B, respectively.
DISCUSSION
Corticosteroids have been used widely for decades as part of immunosuppressive therapy in OLT despite their various associated long term adverse effects. In an attempt to reduce or avoid CS adverse effects, several transplant centers have successfully tried CS minimization or early CS withdrawal protocols post-OLT (4-11) and have reported similar graft failure rates with reduction and better control of hypertension, diabetes, obesity, and hypercholesterolemia, which are major risk factors known to accelerate atherosclerotic heart disease (10, 12) . In recent years, a few CS-free immunosuppressive protocols have been proposed post-OLT (7) (8) (13) (14) (15) (16) (17) (18) (19) . Some CS-free protocols included the use of intra-operative dose of CS followed by post-OLT CS-free maintenance therapy (8, (20) (21) (22) (23) (24) . Although CSfree protocols were reported to be safe compared to historical controls, these regimens have not been widely adopted by many transplant programs. Our aim was to evaluate the safety and efficacy of complete CS-avoidance compared to standard CS-containing immunosuppressive regimen consisting of basiliximab induction and tacrolimus, EC-MPS maintenance immunosuppression in adult OLT recipients.
The protective effect of CS treatment in ameliorating ischemia-reperfusion (I-R) injury and reducing acute rejection in deceased-donor OLT has been verified in a prospective randomized study (25) . However, this approach was questioned by animal studies which showed that CS given at the time of transplantation could enhance I-R injury by increasing DNA fragmentation, and apoptosis after reperfusion (26) , and by inhibiting TNF and IL-6 expression, which impairs cell-cycle progression, and hepatocyte regeneration (27) . Our trial showed no difference in the incidence of I-R injury between CS-containing and CS-free groups, supporting Pirenne's (10) findings that intra-operative high dose CS bolus has no protective effect on I-R injury.
A recent meta-analysis of 19 randomized trials which compared CS-treated to CSfree immunosuppression reported that the CS-free groups demonstrated a trend toward lower hypertension and statistically significant reduction in cholesterol levels and CMV infection (28) . Contrary to these results our prospective randomized trial did not show any difference between the two groups in the incidence of hypertension, cholesterol levels or CMV infection. Although not significant, our results showed a tendency toward increased weight gain in the CS-treated group, which is an anticipated consequence of long term CS use. This disparity may be explained by the heterogeneity of immunosuppressive protocols used by the individual centers, the short period of follow up and the small sample size of the various trials in the meta-analysis groups. The meta-analysis also suggested that the risk of NODM would be markedly lower in the CS-free arm if CS were replaced with another immunosuppressive agent such as an anti-IL2 antibody, polyclonal anti-T-cell antibody or MMF, which was not demonstrated in our study. Our study also showed that FBS levels were similar between groups except at 6 months post-OLT when they were higher in the CStreated group. The reason for this unexpectedly higher glucose level at 6 months is unclear considering that most recipients in the CS-treated group were no longer on CS by 6 months post-OLT.
Our study showed an overall low ACR rate of 5% and similar 1-, 3-, and 5-year patient and graft survival rates between CS-containing and CS-free groups. These may be attributed to the use of anti-IL2 induction in combination with dual CNI/MPA maintenance immunotherapy.
HCV recurrence post-OLT is almost a universal phenomenon. The incidence of histological HCV recurrence ranges from 14% to 72% (29) (30) . Furthermore, a severe cholestatic type of recurrent HCV, characterized by rapid progression to graft failure requiring re-transplantation within 2 years, has been reported in about 10% of HCV recipients (31) (32) . Contrary to these findings, our study showed higher overall incidence of histologic HCV recurrence (81%), and severe cholestatic HCV recurrence (28%).
Furthermore, although the mean PCR levels peaked higher and earlier in the steroid group compared to steroid-free group, there was no difference in the incidence and severity of HCV recurrence, treatment outcomes, and graft loss rates between the two groups. However, studies on de novo use of EC-MPS in OLT recipients have been limited to conversion from MMF to EC-MPS (36) (37) (38) . One study analyzed and showed that EC-MPS has similar efficacy to MMF as a primary immunosuppressant or as an MMF replacement in OLT recipients (39) . Our data showed that EC-MPS was well tolerated with similar incidence of side effects between CS-treated and CS-free groups, most of which resolved with dose reduction. Neutropenia was observed less frequently in the CS-treated group, which could explain why over 90% in this group tolerated optimal dosing of EC-MPS. We suggest that the low incidence of neutropenia in the CS-treated group may be related to the effect of CS in increasing white blood cell count.
In this study, no recipient with autoimmune-mediated liver disorder, i.e., primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis, was randomized in the CS-free group. It is well recognized that this subgroup of recipients may develop disease recurrence in the liver allograft and reported to have a higher incidence of acute and chronic ACR and perhaps may benefit from continuous, long term CS immunoprophylaxis (40) (41) . Consequently, extra caution should be exercised when selecting recipients who can safely be included in a completely CS-free regimen.
In conclusion, our analysis suggests that complete CS avoidance in adult OLT using basiliximab induction with CNI and EC-MPS maintenance is as safe and as effective as standard CS-containing immunosuppression when evaluating for graft function, acute rejection, and patient and graft survival. Contrary to other studies, our results did not show any significant difference between CS-treated and CS-free groups in the incidence of hypertension, hypercholesterolemia, NODM, and weight gain. Furthermore, our data did not validate the common belief that CS-free immunosuppression has a beneficial effect in reducing the incidence, severity or degree of progression of HCV recurrence post-OLT. Tacrolimus was started at 0.10 mg/kg/day by mouth (PO) or nasogastric tube (NGT) in 2 divided doses, within 48 hrs after reperfusion. The dose was adjusted to achieve target trough level 8-12 ng/ml in first month post-OLT, and 5-8 ng/ml, thereafter. All recipients received MMF 1 g every 12 hours via NGT until they could take oral medications, after which they were switched to EC-MPS 720 mg PO twice daily for three months post-OLT.
MATERIALS AND METHODS

Institutional
Recipients were randomized into either treatment arms: Control arm (group A) -standard immunosuppression with CS; and CS-free arm (group B) -standard immunosuppression without CS. Group A received methylprednisolone 1 g IV intraoperatively followed by a taper schedule as follows: methylprednisolone 50 mg IV every 6 hours on day 1; 40 mg IV every 6 hours on day 2; 30 mg IV every 6 hours on day 3; 20 mg IV every 6 hours on day 4; 20 mg IV every 12 hours on days 5; and thereafter, prednisone 20 mg PO daily which was tapered off by 6 months post-OLT. Group A and B recipients were on maintenance CNI monotherapy by 6 months and 3 months post-OLT, respectively.
All recipients received cytomegalovirus (CMV) prophylaxis with IV gancyclovir or valgancyclovir 450 mg PO daily for at least 3 months. They also received prophylactic doses of trimethoprim sulfa 3 times weekly and nystatin swish and swallow 3 times daily.
Liver biopsies were performed according to protocol intra-operatively, between days 7 and 21 post-OLT and at 3-6 months post-OLT, and when clinically indicated. For HCV (+) 13 recipients, quantitative HCV RNA PCR serum levels were performed at baseline, 0.5, 1, 3, and 6 months post-OLT.
Biopsy-proven ACR using the Banff Classification (42) was treated in both groups with methylprednisolone 1 g IV followed by a 5-day CS taper as described above. For recipients in group B who received CS for ACR, prednisone was tapered off by the third month after CS initiation. The protocol also required a repeat biopsy if there was no improvement in the liver function test at the end of CS taper.
A diagnosis of HCV recurrence was made based on liver biopsy findings and serum HCV RNA titers. Recipients with HCV recurrence were treated according to TJUH protocol as described below. Abnormal liver function tests were evaluated by hepatic ultrasound, and percutaneous liver biopsy. The TJUH protocol follows the modified Scheuer scoring system New onset diabetes mellitus (NODM) was defined as FBS ≥ 126 mg/dl (7 mmol/l), with fasting defined as no caloric intake for at least 8 hours.
STATISTICAL ANALYSIS:
Statistical analysis was done to demonstrate equivalence or non-inferiority of the CS-free immunosuppressive regimen compared to the standard protocol with CS for both primary and secondary end points. 
